The Business Journals

Emergent BioSolutions' Baltimore plant nears approval to resume emergency vaccine production

Emergent BioSolutions stopped production in April. The Food and Drug Administration is close to authorizing Emergent BioSolutions’ Baltimore facility to produce Covid-19 vaccine, the Wall Street ...
CNN

FDA OK’s Emergent BioSolutions plant to resume manufacturing J&J’s Covid-19 vaccine

Emergent BioSolutions announced Thursday that the US Food and Drug Administration will allow it to resume the manufacturing of the drug substance that goes into Johnson & Johnson’s Covid-19 vaccine.
The New York Times

Emergent Hid Evidence of Covid Vaccine Problems at Plant, Report Says

The report sheds new light on executives’ worries about deficiencies in the company’s quality control systems at its troubled Baltimore plant; no contaminated doses were ever released to the public.